Artist's rendition of a yellow CAR T cell near a red cancer cell surrounded by red blood cells.
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free
First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.
ABOVE: © ISTOCK.COM, TTSZ
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free

First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.

First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.

ABOVE: © ISTOCK.COM, TTSZ
CAR T cells
knitted pink heart with a mended hole
CAR T Cells Mend Broken Mouse Hearts
Sophie Fessl | Jan 6, 2022
Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Amanda Heidt | Mar 26, 2021
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
An Improved Way to Detect CAR T Cells and SARS-CoV-2-Binding Cells
Technique Talk: An Improved Way to Detect CAR T Cells and SARS-CoV-2-Binding Cells
The Scientist Creative Services Team, Bio-Techne | Apr 13, 2022
Jody Bonnevier will discuss the advantages of Fluorokines™ for detecting and investigating CAR T cells and other key drivers of the immune system.
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena | Mar 5, 2021
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
CAR T cells, oncolytic virus, CD19, mouse model, solid cancer, liquid cancer, tumor, immune response, immunotherapy, T cell, treatment
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
800x560 istock image
Training Immune Cells to Be Cancer Killers
Aparna Nathan | Nov 12, 2021
A career-altering experience as a cancer patient motivated one researcher to design more potent immunotherapies.
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020
There’s a new cell-based cancer immunotherapy on the block.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
Amy Schleunes | Mar 24, 2020
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
Finding CAR T Cells in Solid Tumors by Single-Cell Resolution
Finding CAR T Cells in Solid Tumors at Single-Cell Resolution
The Scientist Creative Services Team in collaboration with Miltenyi Biotec | Nov 12, 2021
Rita Pfeifer will discuss visualizing and quantifying CAR T-cell infiltration into solid tumors with 3-D light sheet fluorescence microscopy (LSFM).
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
Ashley Yeager | Feb 6, 2020
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
car t chimeric antigen receptor t cell immunotherapy pyroptosis cell death perforin macrophage leukemia lymphoma
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Kerry Grens | Jan 20, 2020
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.
Understand Immune Cell Function in Cancer
Understanding Immune Cell Function in Cancer
The Scientist Creative Services Team, Isoplexis | Oct 12, 2021
Explore how scientists characterize immune cell functional behavior in response to cancer, and how they harness this information for therapeutic purposes.
A Bright Scientific Future
Bob Grant | Jan 13, 2020
We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.
cardiac fibrosis car t chimeric antigen receptor immunotherapy t cells fibroblasts cardiovascular disease
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
Emma Yasinski | Sep 11, 2019
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
stn-sept-14-story-1-thumbnail-800x560
Heating Up CAR T Cells for Cancer Therapy
Roni Dengler, PhD | Sep 10, 2021
Heated gold nanoparticles unleash the therapeutic activity of engineered CAR T cells.
cryopreservation facility
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
car t cell chimeric antigen receptor b cell lymphoma cd19 kymriah yescarta
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
800x560-sept-27-2
Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
The Scientist Creative Services Team in Collaboration with IsoPlexis | Sep 7, 2021
David Miklos discusses recent advances in bispecific CAR-T therapy development.
Chronic lymphocytic leukemia
T Cell Proliferation Linked to CAR T Responses
Ashley Yeager | Jul 15, 2019
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.